EA201500932A1 - Твердая пероральная дозированная композиция ингибитора hcv в аморфном состоянии - Google Patents

Твердая пероральная дозированная композиция ингибитора hcv в аморфном состоянии

Info

Publication number
EA201500932A1
EA201500932A1 EA201500932A EA201500932A EA201500932A1 EA 201500932 A1 EA201500932 A1 EA 201500932A1 EA 201500932 A EA201500932 A EA 201500932A EA 201500932 A EA201500932 A EA 201500932A EA 201500932 A1 EA201500932 A1 EA 201500932A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solid oral
dosage forms
oral dosage
compound
hcv inhibitor
Prior art date
Application number
EA201500932A
Other languages
English (en)
Other versions
EA032322B1 (ru
Inventor
Читра Теланг
Зерень Ван
Ли Чжон
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201500932A1 publication Critical patent/EA201500932A1/ru
Publication of EA032322B1 publication Critical patent/EA032322B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В данной заявке описываются твердые пероральные дозированные формы, содержащие соединение (1) или его фармацевтически приемлемую сольгде соединение (1) находится в аморфном состоянии. Также описываются твердые пероральные дозированные формы, включающие композицию соединения (1) в аморфном состоянии и один или более фармацевтически приемлемых наполнителей. Соединение (1) представляет собой специфический ингибитор серинпротеазы вируса гепатита С (HCV) NS3/4A. В данной заявке также описываются способы применения твердых пероральных дозированных форм для лечения инфекции HCV. Также описываются процессы для производства твердых пероральных дозированных форм.
EA201500932A 2013-03-15 2014-03-13 Твердая пероральная дозированная композиция ингибитора hcv в аморфном состоянии EA032322B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791093P 2013-03-15 2013-03-15
PCT/US2014/026028 WO2014151575A1 (en) 2013-03-15 2014-03-13 Solid oral dosage formulation of hcv inhibitor in the amorphous state

Publications (2)

Publication Number Publication Date
EA201500932A1 true EA201500932A1 (ru) 2016-03-31
EA032322B1 EA032322B1 (ru) 2019-05-31

Family

ID=50771327

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500932A EA032322B1 (ru) 2013-03-15 2014-03-13 Твердая пероральная дозированная композиция ингибитора hcv в аморфном состоянии

Country Status (16)

Country Link
US (1) US9732076B2 (ru)
EP (1) EP2968154B1 (ru)
JP (1) JP6130585B2 (ru)
KR (1) KR20150129005A (ru)
CN (1) CN105228593B (ru)
AU (1) AU2014233705C1 (ru)
BR (1) BR112015021692A2 (ru)
CA (1) CA2903831A1 (ru)
CL (1) CL2015002681A1 (ru)
EA (1) EA032322B1 (ru)
IL (1) IL240840A0 (ru)
MX (1) MX364431B (ru)
PH (1) PH12015502258B1 (ru)
SA (1) SA515361071B1 (ru)
UA (1) UA116237C2 (ru)
WO (1) WO2014151575A1 (ru)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
PT1654261E (pt) * 2003-05-21 2008-01-18 Boehringer Ingelheim Int Compostos inibidores da hepatite c
BRPI0511900A (pt) 2004-06-08 2008-01-22 Vertex Pharma composições farmacêuticas
AU2007226983A1 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CA2699335A1 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg. Solid dispersion product containing n-aryl urea-based compound
PE20110388A1 (es) * 2008-09-16 2011-07-01 Boehringer Ingelheim Int Formas cristalinas de un derivado de peptido como inhibidores de hcv
SG2014008981A (en) * 2009-02-27 2014-04-28 Ortho Mcneil Janssen Pharm Amorphous salt of a macrocyclic inhibitor of hcv
CA2767692C (en) * 2009-07-07 2017-03-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2797586A1 (en) * 2011-12-29 2014-11-05 AbbVie Inc. Solid compositions comprising an hcv inhibitor

Also Published As

Publication number Publication date
KR20150129005A (ko) 2015-11-18
PH12015502258A1 (en) 2016-02-01
IL240840A0 (en) 2015-10-29
UA116237C2 (uk) 2018-02-26
WO2014151575A1 (en) 2014-09-25
CN105228593A (zh) 2016-01-06
JP2016514156A (ja) 2016-05-19
EP2968154B1 (en) 2020-06-17
CL2015002681A1 (es) 2016-04-08
MX2015012936A (es) 2015-12-03
BR112015021692A2 (pt) 2017-07-18
SA515361071B1 (ar) 2017-11-29
PH12015502258B1 (en) 2016-02-01
CA2903831A1 (en) 2014-09-25
EA032322B1 (ru) 2019-05-31
US9732076B2 (en) 2017-08-15
AU2014233705C1 (en) 2019-10-10
MX364431B (es) 2019-04-26
JP6130585B2 (ja) 2017-05-17
EP2968154A1 (en) 2016-01-20
CN105228593B (zh) 2018-08-28
US20160185767A1 (en) 2016-06-30
AU2014233705B2 (en) 2019-01-03
AU2014233705A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
EA201591220A1 (ru) Новые противовирусные агенты против инфекции вирусом гепатита в
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
EA201270423A1 (ru) Ингибиторы протеазы hcv
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
IN2014CN03113A (ru)
NO20090453L (no) Hepatitt C Virusinhibitorer
EA201492188A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201171208A1 (ru) Ингибиторы вируса гепатита с
EA201101082A1 (ru) Ингибиторы вируса гепатита с
EA201370017A1 (ru) Ингибиторы вируса гепатита с
EA201591702A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
EA201290575A1 (ru) Ингибиторы вирусов flaviviridae
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
EA201100506A1 (ru) Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
EA201391685A1 (ru) Ингибиторы вируса гепатита с
EA202091113A1 (ru) Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
RU2015114543A (ru) Способы лечения гепатита с
WO2013106689A8 (en) Hcv ns3 protease inhibitors
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
EA201200650A1 (ru) Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU